Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC

Published:2024-12 Issue:13 Volume:34 Page:102699
ISSN:2950-3930
Container-title:The French Journal of Urology
language:en
Short-container-title:The French Journal of Urology

Author:

Abou Chaaya Carla,Ourfali Said,Marchand Chloe,Merienne Camille,Ruffion Alain,Brouzes Hugo,Abid Nadia,Pirot Fabrice,Colombel Marc

Publisher

Elsevier BV

Reference22 articles.

1. Intermediate-risk non-muscle-invasive Bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group;Tan;Eur Urol Oncol,2022

2. French AFU Cancer Committee Guidelines – update 2022–2024: non-muscle-invasive bladder cancer (NMIBC);Neuzillet;Prog Urol,2022

3. European Association of Urology guidelines on non-muscle-invasive Bladder cancer (Ta, T1, and carcinoma in situ);Babjuk;Eur Urol,2022

4. Intravesical gemcitabine for non-muscle invasive bladder cancer;Han;Cochrane Database Syst Rev,2021

5. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance;Addeo;J Clin Oncol,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP